Pharmaceutical News

RSS

Cepacol introduces instant pain relief tablets for children with sore throats

As a leader in the Lozenge Category, Cepacol(R) has announced the introduction of Cepacol(R) Fizzlers(TM), a single symptom sore throat relief product designed specifically for kids.

17 Sep 2009

BioMedReports.Com's news report on CEL-SCI's key developments

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special news report on key developments at CEL-SCI Corporation.

17 Sep 2009

NCPA happy with Baucus' proposals for community pharmacies

The National Community Pharmacists Association (NCPA) commended Senate Finance Committee Chair Max Baucus (D-MT) for including several critical provisions to help community pharmacies better serve patients in the “America’s Healthy Future Act” proposed today.

17 Sep 2009

Mechanism of action of the anti-cancer drug GMX1778 identified

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying the mechanism of action of the anti-cancer drug GMX1778. Co-authored by scientists at Gemin X Pharmaceuticals and Metabolon, the paper “The Small Molecule GMX1778 is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in NAPRT1-Deficient Tumors” appears online ahead of print in Molecular and Cellular Biology.

17 Sep 2009

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Attempts to eradicate tuberculosis (TB) are stymied by the fact that the disease-causing bacteria have a sophisticated mechanism for surviving dormant in infected cells. Now, a team of scientists led by researchers from Weill Cornell Medical College has identified compounds that inhibit that mechanism -- without damaging human cells.

17 Sep 2009

FDA issues a complete response letter for Sanofi-aventis' eplivanserin NDA

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the company's New Drug Application (NDA) for eplivanserin (Ciltyri(R)). Eplivanserin was reviewed as a potential treatment for patients with chronic insomnia characterized by difficulties with sleep maintenance.

17 Sep 2009

Weis Markets to hold low-cost flu shot program

Beginning this month, Weis Markets will hold more than 100 low-cost flu shot clinics in its Maryland, New Jersey, Pennsylvania and West Virginia stores. In addition, as part of its WEISCARE Adult Immunization program, many Weis Markets' pharmacies will offer flu shots as an on-going service.

17 Sep 2009

DNage's observational study assesses natural progression of CS in children

Biotech company Pharming Group NV ("Pharming" or "the Company") announced today that its wholly-owned subsidiary DNage has initiated an observational study in children suffering from Cockayne Syndrome (CS).

17 Sep 2009

IPTi tool with SP medicine helps prevent malaria in African infants

A third (30%) of malaria cases can be avoided in African infants using a safe, affordable and simple tool called Intermittent Preventive Treatment of malaria in Infants (IPTi) with the medicine sulphadoxine-pyrimethamine (SP), which can be delivered alongside existing childhood vaccination programmes.

17 Sep 2009

APP Pharmaceuticals announces FDA marketing approval of Deferoxamine Mesylate

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine Mesylate is therapeutically equivalent to the reference-listed drug Desferal®, which is marketed by the innovator Novartis.

17 Sep 2009

Study: Therapy addition reduces risk of stroke and other cardiovascular events

Data from the independent KYOTO HEART study, presented recently at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, and published online in the European Heart Journal demonstrated the addition of the angiotensin receptor blocker (ARB) Diovan (valsartan) to a non-ARB-based treatment regimen for high blood pressure provided a significant 45% relative risk reduction in cardiovascular events(1) including stroke, compared to conventional non-ARB treatment regimen.(1)

17 Sep 2009

Genentech releases Phase III PRIMA study findings

Genentech, Inc., a wholly-owned member of the Roche Group and Biogen Idec, today announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan.

17 Sep 2009

Fully-insured members of Capital BlueCross to receive coverage for administration fee for H1N1 Flu vaccine

Capital BlueCross announced today that it will cover an administration fee for the H1N1 Flu vaccine for fully-insured members and those with individual coverage during the upcoming 2009-2010 flu season. Self-funded groups may opt to have their coverage customized to include this benefit.

17 Sep 2009

GENova to sign extensive collaboration agreement with Beckpharma

GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it is in final negotiations with Beckpharma Ltd. ("Beckpharma") -a pharmaceutical development company also involved in cancer treatments for an extensive collaboration agreement.

17 Sep 2009

FDA approves Sirion's Zirgan for treating acute herpetic keratitis

Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved its New Drug Application for Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% as a treatment for acute herpetic keratitis (dendritic ulcers). The FDA granted orphan drug designation to Zirgan for this indication in April 2007.

17 Sep 2009

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a unanimous vote of 12 to 0 that XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing approval by the FDA for the treatment of Dupuytren's contracture.

17 Sep 2009

Administrative cost of H1N1 vaccine to be covered for CIGNA's customers

The spread of the H1N1 influenza virus has the potential to make this year’s flu season more severe than usual. The Centers for Disease Control and Prevention (CDC) has designated vaccination as the most powerful public health tool to control influenza.

17 Sep 2009

BioSpecifics Technologies' XIAFLEX receives marketing approval from FDA

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced that the Arthritis Advisory Committee appointed by the U.S.

17 Sep 2009

OCLS' partnership with V&M Industries to market Microcyn-based skin and wound care products

Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat infections in chronic and acute wounds, announced today it has entered into a new strategic partnership with V&M Industries, Inc. for non-exclusive rights to market Microcyn-based skin and wound care over-the-counter products in the United States and Canada while providing Oculus with a significant percentage of those revenues.

16 Sep 2009

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

AEterna Zentaris Inc., ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.

16 Sep 2009